Omeros Corp. reported a net loss of $39.5 million, or $0.81 per share, in the third quarter of 2018 compared to a net loss of $7.5 million, or $0.16 per share, in the third quarter of 2017.
Revenues for the quarter decreased from $21.7 million in 2017 to $4.6 million in 2018, all related to sales of Omidria, according to a company press release.
The decrease was attributed to a reduction in Omidria use among ASCs and hospitals in the absence of a transitional pass-through reimbursement. The third quarter revenue (Read more...)
Uncategorized